Tapewire

Nasdaq · USD

TLX

Telix Pharmaceuticals Ltd

Export transactions ↓
Tapewire entity
4101
SEC CIK
0002007191
Parsed reports
13

Last 12 months

Inside the activity.

3 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202600
Mar 202600
Apr 202620
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202610
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
September 07, 2026 Filed Sep 14, 2026 23:20 UTC
Smith Darren CharltonGroup Chief Financial Officer
PurchaseOrdinary Shares 2,071 $9.66 $19,997.58
Disclosure

SEC source: 0001628280-26-061944 · wk-form4_1789428011.xml · nonDerivative · entry 1

Smith Darren Charlton · CIK 0002122447 · Group Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,992

F1 · shares: Represents shares purchased by the Reporting Person under the Employee Share Purchase Plan section of the Issuer's Equity Incentive Plan ("AU ESPP"), which shares were allocated on September 7, 2026, based on the Reporting Person's contributions to the AU ESPP from January 1, 2026 - June 30, 2026.

F2 · price: Purchase price is recorded in Australian Dollars.

Read SEC document
April 29, 2026 Filed May 7, 2026 01:32 UTC
Behrenbruch ChristianDirector · MD & Group CEO
PurchaseOrdinary Shares 33,435 $14.87 $497,178.45
Disclosure

SEC source: 0001628280-26-031608 · wk-form4_1778117523.xml · nonDerivative · entry 2

Behrenbruch Christian · CIK 0002037713 · Director · MD & Group CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · Elk River Holdings Pty Ltd

Disclosed balance after: 20,742,935

F2 · price: The purchase prices are reported in Australian Dollars.

F4 · price: The price reported in Column 4 is an average price. The shares were purchased in multiple transactions at prices ranging from $14.54 - $14.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4.

F3 · ownership.nature: Dr. Behrenbruch is the sole director and shareholder of Elk River Holdings Pty Ltd.

Read SEC document
April 28, 2026 Filed May 7, 2026 01:32 UTC
Behrenbruch ChristianDirector · MD & Group CEO
PurchaseOrdinary Shares 34,500 $14.48 $499,560.00
Disclosure

SEC source: 0001628280-26-031608 · wk-form4_1778117523.xml · nonDerivative · entry 1

Behrenbruch Christian · CIK 0002037713 · Director · MD & Group CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · Elk River Holdings Pty Ltd

Disclosed balance after: 20,709,500

F1 · price: The price reported in Column 4 is an average price. The shares were purchased in multiple transactions at prices ranging from $14.42 - $14.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (SEC), upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

F2 · price: The purchase prices are reported in Australian Dollars.

F3 · ownership.nature: Dr. Behrenbruch is the sole director and shareholder of Elk River Holdings Pty Ltd.

Read SEC document
March 29, 2026 Filed Apr 1, 2026 23:14 UTC
Smith Darren CharltonGroup Chief Financial Officer
Exercise / conversionShare Rights · Derivative 1,111 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001628280-26-022909 · wk-form4_1775085272.xml · derivative · entry 2

Smith Darren Charlton · CIK 0002122447 · Group Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 1,111 shares

Expires 2028-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The share rights (SRs) were granted on January 1, 2025 and became vested and exercisable on March 5, 2026.

Read SEC document
March 29, 2026 Filed Apr 1, 2026 23:14 UTC
Smith Darren CharltonGroup Chief Financial Officer
Exercise / conversionOrdinary Shares 1,111 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-022909 · wk-form4_1775085272.xml · nonDerivative · entry 1

Smith Darren Charlton · CIK 0002122447 · Group Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,921

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.